Bladder cancer Flashcards
Perioperative chemotherapy(neoadjuvant or adjuvant) Standard regimen
- DDMVAC (dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin) with growth factor support for 3 or 4 cycles
- Gemcitabine and cisplatin for 4 cycles
- CMV (cisplatin, methotrexate, and vinblastine) for 3 cycles
First-line chemotherapy for locally advanced or metastatic disease Cisplatin eligible(Standard regimen)
- Gemcitabine and cisplatin4 (category 1)
- DDMVAC with growth factor support (category 1)
First-line chemotherapy for locally advanced or metastatic disease
Cisplatin ineligible with poor kidney function or poor PS
Standard regimen
- Gemcitabine and carboplatin
Alternate regimen for select patient
- Gemcitabine
- Gemcitabine and paclitaxel
First-line chemotherapy for locally advanced or metastatic disease
Cisplatin ineligible due to hearing/ neuropathy but with good kidney function, and good PS
Alternate regimen for select patient
-Ifosfamide, doxorubicin and gemcitabine
Second-line systemic therapy for locally advanced or metastatic disease
Standard regimen
- Atezolizumab
- Paclitaxel or docetaxel
- Gemcitabine
- Pemetrexed
Second-line systemic therapy for locally advanced or metastatic disease
Alternate regimen for select patient Nab-paclitaxel Ifosfamide Methotrexate Ifosfamide, doxorubicin, and gemcitabine Gemcitabine and paclitaxel Gemcitabine and cisplatin DDMVAC
Radiosensitizing chemotherapy regimens for bladder-preserving chemoradiation following a maximal TURB
First line chemotherapy
Standard regimen
- Cisplatin and 5-FU
- Cisplatin and paclitaxel
- 5-FU and mitomycin
Alternate regimen
- Cisplatin alone
- Low-dose gemcitabine(category 2B)
Radiosensitizing chemotherapy given concurrently with conventionally fractionated radiation for palliation of metastases or for pelvic recurrence after cystectomy
- Cisplatin
- Taxane (docetaxel or paclitaxel) (category 2B)
- 5-FU (category 2B)
- 5-FU and mitomycin (category 2B)
- Capecitabine (category 3)
- Low-dose gemcitabine (category 2B)